Mayne Pharma Group
MYX.AXMYX.AX · Stock Price
Historical price data
Overview
Mayne Pharma is a specialty pharmaceutical company with a mission to improve patient access to life-enhancing medications through a dual-pillar strategy of proprietary product commercialization and contract services. The company has achieved significant commercial traction in the US with its Women's Health and Dermatology portfolios, supported by a deep expertise in complex oral and topical drug delivery systems. Its current strategic focus is on executing growth within its core therapeutic areas, managing the recently announced acquisition scheme with Cosette Pharmaceuticals, and optimizing its capital allocation to drive shareholder value.
Technology Platform
Core expertise in complex drug delivery systems, including proprietary platforms for bioavailability enhancement (SUBA®), taste-masking (CLEANTASTE®), and controlled-release pellet technologies for oral and topical dose forms.
Pipeline
12| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Sporanox + Lozanoc | Neutropenia | Approved | |
| Halobetasol Topical Foam | Plaque Psoriasis | Approved | |
| Doxycycline Hyclate Delayed-Release 200 mg | Gonorrhea | Approved | |
| Slow release oral morphine (SROM) + Methadone | Opioid-Related Disorders | Phase 3 | |
| Permethrin Cream, 5% + Elimite | Scabies | Phase 3 |
Opportunities
Risk Factors
Competitive Landscape
Competes in branded specialty pharma against large-cap players and focused rivals, and in generics against firms with complex capabilities. Differentiation is achieved through proprietary drug delivery technology and a focus on 505(b)(2) products with limited competition.